Stock Financial Ratios

MRNS / Marinus Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)185.47
Enterprise Value ($M)100.17
Book Value ($M)21.48
Book Value / Share1.10
Price / Book2.99
NCAV ($M)23.36
NCAV / Share1.20
Price / NCAV2.91
Income Statement (mra) ($M)
Net Income-28.64
Balance Sheet (mrq) ($M)
Cash & Equivalents37.53
Cash / Share1.92
Quick Ratio3.75
Current Ratio3.75
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.95
Return on Assets (ROA)-0.91
Return on Equity (ROE)-1.33
Identifiers and Descriptors
Central Index Key (CIK)1267813
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)40.43
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Assets Per Share3.32
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Assets Current Per Share2.23
Debt Per Share0.00
Inventory Per Share0.00
Liabilities Per Share0.13
Additional Paid In Capital Per Share10.36
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Property Plant And Equipment Net Per Share0.06
Liabilities Current Per Share0.12
Goodwill Per Share0.00
Retained Earnings Per Share-7.18
Equity Per Share3.18
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Cash And Equivalents Per Share1.92
Accumulated Depreciation And Depletion Per Share0.00
Cash Per Share1.92
Liabilities And Stock Equity Per Share3.32
Minority Interest Per Share0.00
Property Plant And Equipment Per Share0.06

Related News Stories

Sage's PhIII Success In PPD: What It Means For Marinus Pharmaceuticals

2017-11-10 seekingalpha
Sage's IV formulation of allopregnanolone succeeds in PPD, ushering in a new era for the treatment of depressive disorders. (71-1)

Marinus Pharmaceuticals: The Next Big Thing In CNS

2017-10-31 seekingalpha
Orphan drug designation, paired with unprecedented data, enables expedited approval of Ganaxolone in CDKL5 and additional orphan pediatric indications. (165-2)

Can Pharma Succeed In A Condition Impacting 1 In 68 Children?

2017-10-31 seekingalpha
The pharmaceutical industry has struggled to address autism due to its heterogeneity, with only two medications approved for any autism symptom - both of which were blockbusters. (104-2)

PRO Weekly Digest: All About mREITs And BDCs With Scott Kennedy

2017-10-08 seekingalpha
The benefits of having an accounting background, financial modeling and dividend sustainability are topics discussed, and Scott Kennedy shares a bullish thesis on mREIT preferreds. (210-0)

BRIEF-Bain Capital Life Sciences Fund reports 14.4 pct passive stake in Marinus Pharmaceuticals

2017-09-28 reuters
* Bain Capital Life Sciences Fund L.P reports 14.4 percent passive stake in Marinus Pharmaceuticals Inc as of Sept 19, 2017 - SEC filing Source text for Eikon: ( Further company coverage: (71-1)

CUSIP: 56854Q101